Literature DB >> 33530037

Prevalence and risk factors of myasthenia gravis recurrence post-thymectomy.

Fatmah Alqarni1, Daifallah Almalki1, Ziyad Aljohani1, Abdulrahman Ali1, Alanood AlSaleem1, Noura Alotaibi1, Shahla Odeh1, Sultan Al Dalbhi1.   

Abstract

OBJECTIVES: To evaluate the prevalence and the factors associated with recurrence of myasthenia gravis following thymectomy.
METHODS: Six electronic databases which reported on recurrence of myasthenia gravis following thymectomy and/or its risk factors from 1985 to 2018 were searched. Summary prevalence and risk values obtained based on the random effect models were reported.
RESULTS: Seventy (70) papers containing 7,287 individuals with myasthenia gravis who received thymectomy as part of their management were retrieved. The patients had a mean follow-up of 4.65 years post-thymectomy. The prevalence of myasthenia gravis recurrence post-thymectomy was 18.0% (95% CI 14.7-22.0%; 1865/7287). Evident heterogeneity was observed (I2=93.6%; p<0.001). Recurrence rate was insignificantly higher in male compared with female patients (31.3 vs. 23.8%; p=0.104). Pooled recurrence rates for thymomatous (33.3%) was higher than the rate among non-thymomatous (20.8%) myasthenia gravis patients (Q=4.19, p=0.041). Risk factors for recurrence include older age, male sex, disease severity, having thymomatous myasthenia gravis, longer duration of the myasthenia gravis before surgery, and having an ectopic thymic tissue.
CONCLUSION: A fifth of individuals with myasthenia gravis experience recurrence after thymectomy. Closer monitoring should be given to at-risk patients and further studies are needed to understand interventions to address these risks. Copyright: © Neurosciences.

Entities:  

Mesh:

Year:  2021        PMID: 33530037     DOI: 10.17712/nsj.2021.1.20190041

Source DB:  PubMed          Journal:  Neurosciences (Riyadh)        ISSN: 1319-6138            Impact factor:   0.906


  1 in total

1.  Early Flare-Ups of Myasthenia Gravis After Thoracoscopic Thymectomy in a Patient Recently Receiving BNT162b2 mRNA COVID-19 Vaccination.

Authors:  Permphan Dharmasaroja
Journal:  Cureus       Date:  2022-01-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.